Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This $3 BioTech Stock could EXPLODE SOON!! Why?

<< Previous

Bullboard Posts

Next >>

Comment by Pragmatiston Jun 11, 2021 11:16am

128 Views

Post# 33372190

RE:RE:RE:RE:RE:RE:This $3 BioTech Stock could EXPLODE SOON!! Why?

https://trendingmarketnews.com/this-company-could-disrupt-the-approx-24-billion-nsaid-market-with-limited-gastrointestinal-side-effects/?utm_source=Financial%20Ineptitude&utm_medium=Financial%20Ineptitude&utm_campaign=ATE

Here is another one I came across earlier. This one is mostly a rehash of the deck. If you scroll down to the bottom, you will see that TD Media is coordinating this.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand